Altaris Acquires Intricon Corporation

New York, NY—Altaris Capital Partners, LLC (collectively with its affiliates, “Altaris”) announced today that it completed the acquisition of Intricon Corporation (including affiliated entities, “Intricon”), a publicly traded company listed on the NASDAQ stock exchange under the ticker “IIN”. As a result of the acquisition, Intricon is now privately held and its stock will no longer be traded.

Intricon develops and manufactures miniature and micromedical components, sub-assemblies, and devices for the medical device industry. Intricon primarily serves original equipment manufacturers as a contract development and manufacturing organization, leveraging its capabilities in precision molding, micro-electronics, micro-coils, ultra-low power digital signal processing, and complex extrusion. Headquartered in Arden Hills, Minnesota, Intricon employs over 850 employees across four domestic production facilities in Minnesota and California and two international production facilities in Indonesia and Singapore.

ArentFox Schiff LLP and Linklaters LLP acted as legal counsel for Altaris. Capital One served as Lead Left Arranger and J.P. Morgan as Arranger to Altaris. Intricon was advised by Piper Sandler & Co. and Blank Rome LLP.

Altaris is a healthcare investment firm with an exclusive focus on building companies that deliver value to the healthcare system through innovation and efficiency. Since inception in 2003, Altaris has invested in more than 45 healthcare companies which have generated significant value appreciation for investors. Altaris is headquartered in New York City and manages $5.0 billion of equity capital. For more information, please visit www.altariscap.com.